Revvity Inc vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Revvity Inc trades at $154.18 (market cap $16.98B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $25.99 (market cap $2.03B). The key difference: Revvity Inc is far larger — about 8.4× Direxion Daily 20 Year Treasury Bull 3X Shares's market cap, and Revvity Inc pays a 0.18% dividend while Direxion Daily 20 Year Treasury Bull 3X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and Direxion Daily 20 Year Treasury Bull 3X Shares for 28 Days on average.
| RVTY | TMF | |
|---|---|---|
Market Cap | $16.98B | $2.03B |
Volume | 1,456,900 | 12,241,664 |
Sector | Health | Fixed Income |
52-Week High | $157.36 | $44.14 |
52-Week Low | $82.26 | $25.19 |
Typical Hold Time | 12 Days | 28 Days |
Enterprise Value | $19.30B | — |
Dividend Yield | 0.18% | — |
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
TMF (Direxion Daily 20+ Year Treasury Bull 3X ETF) trades at $25.92, up 2.73% with increased volume of 5.2 million shares. Technical indicators show a bearish trend with strong selling pressure in moving averages, while oscillators remain neutral. The ETF saw heightened trading activity amid market focus on long-term Treasury movements.
As a leveraged Treasury ETF, TMF offers amplified exposure to long-term bond performance but carries significant volatility risks. Current market conditions suggest cautious positioning given the bearish technical signals and interest rate sensitivity. The absence of fundamental metrics typical of operating companies limits traditional valuation analysis.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →